Amgen's Kyprolis Miss In First-Line Myeloma Surprising, But Clinically Irrelevant
Executive Summary
Because CLARION was designed to test Kyprolis head-to-head against fellow proteasome inhibitor Velcade, the failure could hurt the drug's standing in its class. But the trial design used a regimen largely phased out of clinical practice and Amgen has other chances to prove superiority.
You may also be interested in...
Late-Breakers To Look Out For At ASCO 2020
ASCO 2020, which takes place from 29-31 May, will necessarily depart from its predecessors in location, content and delivery. Here, with input from Biomedtracker and Datamonitor Healthcare, we take a look at what can be expected during this year’s late-breaking clinical trial sessions.
Myeloma Survival Benefit May Help Amgen's Kyprolis Stave Off Competition
Proving a survival benefit in the head-to-head ENDEAVOR relapsed multiple myeloma study gives Amgen's Kyprolis a leg up ahead of the entry of Velcade generics in the US this year.
Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition
Amgen signaled future declines in revenue for its top-selling product Enbrel during its third quarter conference call as payer pressure on drug pricing and competition mounts.